FDA Approval Alert: The Need-to-Know | Dostarlimab/Chemotherapy in Advanced or Recurrent Endometrial Cancer

In August 2024, the FDA expanded approval status for dostarlimab-gxly plus carboplatin/paclitaxel followed by single-agent dostarlimab to include all adult patients with primary advanced or recurrent endometrial cancer.

Ritu Salani, MD, highlights data from the RUBY trial supporting the FDA approval of dostarlimab/chemotherapy for primary advanced endometrial cancer.

Optimizing Benefits Following Dostarlimab Approval in Endometrial Cancer

Podcast

By Ritu Salani, MD

Aug 19, 2024 12:00 PM

Ritu Salani, MD, highlights data from the RUBY trial supporting the FDA approval of dostarlimab/chemotherapy for primary advanced endometrial cancer.

Ritu Salani, MD, discussed investigational endometrial cancer treatment options for patients with varying subtypes of endometrial cancer.

Selinexor, HER2-Targeting ADC May Provide Options for Endometrial Cancer

Video

By Ritu Salani, MD

Aug 18, 2024 2:00 PM

Ritu Salani, MD, discussed investigational endometrial cancer treatment options for patients with varying subtypes of endometrial cancer.

Comparable Safety Observed in Dostarlimab for Endometrial Cancer Subtypes

Video

By Ritu Salani, MD

Aug 17, 2024 2:00 PM

The second interim analysis of the phase 3 RUBY trial found the safety profile was consistent with the first interim analysis and no new deaths due to AEs were observed.

The phase 3 RUBY trial evaluated dostarlimab in combination with carboplatin/paclitaxel in patients with primary advanced or recurrent endometrial cancer.

Dostarlimab Benefits Appear More Pronounced in dMMR Endometrial Cancer

Video

By Ritu Salani, MD

Aug 16, 2024 6:00 PM

The phase 3 RUBY trial evaluated dostarlimab in combination with carboplatin/paclitaxel in patients with primary advanced or recurrent endometrial cancer.